Rob Dillard

DocwireNews

A study found that JAK2 V617F mutations were associated with improved overall survival (OS) and progression-free survival (PFS) after allogeneic hematopoietic cell transplantation (HCT) in patients with myelofibrosis (MF) after the approval of ruxolitinib in 2011. The findings were <a href="https://ash.confex.com/ash/2023/webprogram/Paper178684.html" target="_blank" rel="noopener">presented</a> at the 65th ASH Annual Meeting &amp; Exposition, which is taking place December 9-12 in San Diego, California.
Mahasweta Gooptu, MD, and colleagues analyzed 166 patients with MF who underwent HCT from 2000 to 2020. They assessed outcomes for the whole group and also conducted subgroup analyses in patients from the pre-2011 (n=39) and post-2011 (n=127) eras.
The analysis showed that OS for the whole cohort was 58%, and PFS was 55%. Four-year OS was significantly better in the post-2011 era compared with pre-2011 (69% vs 26%; P&lt;.0001), as was PFS, largely due to lower relapse rates in the post-2011 era (15% vs 41%; P&lt;.0001). Nonrelapse mortality was also better (20% vs 33%; P=.17) post-2011.
Overall, combining clinical and molecular features post-2011, the study showed that JAK2-positive mutation was significantly associated with better OS and PFS (hazard ratio, 0.32; 95% CI 0.14-0.75; P=.009).
The researchers concluded that &#8220;the presence of a JAK2 V617F mutation was associated with better OS and PFS following HCT in MF in the post-2011 era. Survival outcomes are significantly better in the post-2011 era compared [with] pre-2011 in our cohort.&#8221;
Reference
Gooptu M, Kim H, Chen K, et al. Impact of clinical and genetic factors on myelofibrosis outcomes after allogeneic transplantation. Abstract #4978. Presented at the 65th ASH Annual Meeting &amp; Exposition; December 9-12, 2023; San Diego, California.

Cecilia Brown

Should Post-CCRT Durvalumab Be an Option for Older Patients With Unresectable Stage III NSCLC?

Lung Cancer

Genetics Play a Larger Role in Melanoma Than Previously Thought

Skin Cancer

Jason Okulicz

Remdesivir Reduces Mortality in Elderly Patients Hospitalized With COVID-19

COVID-19

Latest News

Myelofibrosis Outcomes After Allogeneic Transplantation Pre- and Post-2011

Conference Coverage

A study found that JAK2 V617F mutations were associated with improved overall and progression-free survival after HCT in patients with myelofibrosis.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Oncology

Diabetes

Neurology

Rheumatology

Gastroenterology

Pulmonology

Ophthalmology

Infectious Diseases

— HIV

Health and Wellness

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Fellow on Call

Healthcare Unfiltered

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Career Center

Expert Interviews

Subscribe